ALS

Senior consultant neurologist Dr Angelina Hatlø Maniaol is coordinating investigator for the study, which will consist of a 6-month double-blind randomized phase where patients will get either Riluzole or ILB®, followed by a 6-month open-label extension where patients will get both ILB® and Riluzole. The study is sponsored by Oslo University Hospital, funded by public … Läs mer

Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed AB today announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB® is safe and well tolerated in patients with ALS. Eleven patients participated in the prospective, single-arm, open-label, phase II clinical trial encompassing … Läs mer